Archives for 

Amgen v. Hospira (epoetin alfa)

BPCIA Litigation Roundup (Spring 2017)

AbbVie v. Amgen (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Coherus (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  Janssen v. Samsung Bioepis (infliximab)  •  U.S. Biosimilar Litigation News
Below is our spring update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, […]

View More

FDA Advisory Committee Recommends Approval of Pfizer’s EPOGEN®/PROCRIT® Biosimilar

Amgen v. Hospira (epoetin alfa)  •  Approved Biosimilar Products  •  Biosimilar News
As we previously reported, the FDA Oncologic Drugs Advisory Committee (“ODAC”) held a public meeting today regarding Hospira’s application for its proposed biosimilar of Amgen’s Epogen®/Procrit® (epoetin alfa).  Pfizer, Hospira’s parent company, has announced today […]

View More